Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Aldesleukin 18million unit inj vials
0802040AQAAAAAA
|
Aldesleukin | Aldesleukin | Malignant Disease and Immunosuppression | No data available |
|
Alecensa 150mg capsules
0801050CDBBAAAA
|
Alecensa | Alectinib | Malignant Disease and Immunosuppression | No data available |
|
Alectinib 150mg capsules
0801050CDAAAAAA
|
Alectinib | Alectinib | Malignant Disease and Immunosuppression | No data available |
|
Alemtuzumab 12mg/1.2ml solution for infusion vials
0802030E0AAABAB
|
Alemtuzumab | Alemtuzumab | Malignant Disease and Immunosuppression | No data available |
|
Alemtuzumab 30mg/1ml solution for infusion vials
0802030E0AAAAAA
|
Alemtuzumab | Alemtuzumab | Malignant Disease and Immunosuppression | No data available |
|
Alimta 100mg pdr for concentrate for inf vials
0801030Y0BBABAB
|
Alimta | Pemetrexed | Malignant Disease and Immunosuppression | No data available |
|
Alimta 500mg pdr for concentrate for inf vials
0801030Y0BBAAAA
|
Alimta | Pemetrexed | Malignant Disease and Immunosuppression | No data available |
|
Alkeran 2mg tablets
0801010S0BBAAAB
|
Alkeran | Melphalan | Malignant Disease and Immunosuppression | No data available |
|
Alkeran 50mg inj vials
0801010S0BBADAD
|
Alkeran | Melphalan | Malignant Disease and Immunosuppression | No data available |
|
Alkeran 5mg tablets
0801010S0BBABAC
|
Alkeran | Melphalan | Malignant Disease and Immunosuppression | No data available |
|
Alunbrig 180mg tablets
0801050CPBBAAAA
|
Alunbrig | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Alunbrig 30mg tablets
0801050CPBBABAB
|
Alunbrig | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Alunbrig 90mg tablets
0801050CPBBACAC
|
Alunbrig | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Alunbrig 90mg/180mg tablets treatment initiation pack
0801050CPBBADAD
|
Alunbrig | Brigatinib | Malignant Disease and Immunosuppression | No data available |
|
Alymsys 100mg/4ml concentrate for inf vials
0801050APBEAAAA
|
Alymsys | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Alymsys 400mg/16ml concentrate for inf vials
0801050APBEABAB
|
Alymsys | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Amifostine 375mg powder for solution for infusion vials
0801000V0AAAAAA
|
Amifostine | Amifostine | Malignant Disease and Immunosuppression | No data available |
|
Amifostine 500mg powder for solution for infusion vials
0801000V0AAABAB
|
Amifostine | Amifostine | Malignant Disease and Immunosuppression | No data available |
|
Aminoglutethimide 250mg tablets
0803041A0AAAAAA
|
Aminoglutethimide | Aminoglutethimide | Malignant Disease and Immunosuppression | No data available |
|
Amsacrine 75mg/1.5ml inf ampoules and diluent
0801050C0AAAAAA
|
Amsacrine | Amsacrine | Malignant Disease and Immunosuppression | No data available |
|
Amsidine 75mg/1.5ml inf ampoules and diluent (Mercury)
0801050C0BBAAAA
|
Amsidine | Amsacrine | Malignant Disease and Immunosuppression | No data available |
|
Antithymocyte immunoglobulin (rabbit) 25mg inf vials
0802020X0AAAAAA
|
Antithymocyte immunoglobulin | Antithymocyte immunoglobulin | Malignant Disease and Immunosuppression | No data available |
|
Arsenic 10mg/10ml solution for infusion ampoules
0801050AIAAAAAA
|
Arsenic | Arsenic | Malignant Disease and Immunosuppression | No data available |
|
Arzip 250mg capsules
0802010M0BDAAAA
|
Arzip | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Arzip 500mg tablets
0802010M0BDABAB
|
Arzip | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.